Vol 26 No 8 LCGC Europe August 2013 Regular Issue PDF

In this article, the use of comprehensive two-dimensional liquid chromatography (LC×LC) coupled to mass spectrometry (MS) for characterizing glycosylation of therapeutic enzymes is presented.

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.

Davy Guillarme of the Institute of Pharmaceutical Sciences of Western Switzerland and the School of Pharmaceutical Sciences at the University of Geneva (Switzerland) recently spoke with LCGC International about his work analyzing therapeutic oligonucleotides.

In the first LCGC Blog of 2025, Caitlin Cain of the University of Michigan highlights the divide between gas and liquid chromatographers, and why both types of techniques should be in the same conversations.